angiotensin IV is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-06-28. Where a claim depends on a specific study, the study is described rather than over-claimed.
Dihexa is commonly handled as a lyophilized powder in laboratory settings. Storage at -20 °C in a desiccated, light-protected container is typical for peptides. Repeated freeze-thaw cycles can degrade the material, so aliquoting is often recommended. Aqueous solutions may be less stable than organic stocks and should be prepared fresh when possible. Personnel should follow institutional safety procedures and avoid uncontrolled exposure. Because human effects are not well characterized, handling precautions are prudent.
The proposed mechanism of dihexa centers on activation of the hepatocyte growth factor receptor, also called c-Met. Some studies suggest it acts as a mimetic of hepatocyte growth factor, promoting signaling pathways involved in synapse formation. Other work has explored interactions with angiotensin IV pathways, but the exact binding targets remain uncertain. Laboratory findings come mainly from cell cultures and animal models. Whether these mechanisms operate similarly in humans is an open question. Researchers have not established a single, universally accepted mechanism of action.
Identity and purity of dihexa samples are typically assessed with high-performance liquid chromatography and mass spectrometry. These methods can confirm molecular mass and estimate the presence of impurities. However, a certificate of analysis from a supplier is not a guarantee of independent testing. Researchers often require in-house verification before using a peptide in experiments. For solid samples, appearance, solubility, and chromatographic profile provide additional checks. Nuclear magnetic resonance may be used for structural confirmation when available.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
| Property | Value | Notes |
|---|---|---|
| Typical analytical method | LC-MS and HPLC | Used for identity and purity assessment. |
| Purity specification | ≥95% or ≥98% in research grades | Actual purity depends on supplier and batch. |
| Stability in solution | Limited; prepare fresh | Aqueous and organic stocks may degrade over time. |
| Recommended storage | -20 °C, desiccated, protected from light | Reduce freeze-thaw cycles. |
| Regulatory status | Not approved for human use | Sold as a research chemical in some regions. |
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
Dihexa occupies an uncertain regulatory space in many countries. It is not generally listed as an approved therapeutic, and some jurisdictions may treat it as a research chemical, a compounded substance, or an unapproved new drug depending on claims and distribution. Importation can be restricted, and suppliers may require documentation that the material is for laboratory research only. Quality and labeling vary, so buyers should request analytical data, verify lot numbers, and understand local rules. These factors make sourcing and compliance part of the practical context around dihexa.
Lyophilized dihexa is typically stored as a dry powder at or below minus twenty degrees Celsius. Cooler temperatures slow degradation, and desiccant protection limits moisture uptake. Repeated temperature cycling can accelerate breakdown, so aliquoting before storage is common in laboratory practice. Solutions are generally less stable than dry powder and are often kept cold, protected from light, and used within a defined period. Specific stability data for dihexa are limited, and handling recommendations often follow general peptide guidelines rather than compound-specific studies.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
=== Degradative enzymes === Like any second messenger system, the signal must be terminated and there must be routes for NAADP removal but again, little is known with any degree of certainty. A 2'-3'-phosphatase stimulated by Ca2+ has been proposed in brain and, possibly in pancreatic acinar cells, that catabolises NAADP to inactive NAAD. CD38 has also been found to breakdown NAADP (to ADPRP — see inset). NAADP may also be reduced to NAADPH.
== Education == Gattuso earned a bachelor's degree from the University of Nice (1980) and a master's degree in oceanography at the University of Aix-Marseille II. In 1987, he obtained a Ph.D. in oceanography from the University of Aix-Marseille II.
=== Thermal modulation === Thermal modulators use broad temperature differentials (by way of hot and cold jets) to trap and release analytes eluting out of the primary column. Commercial devices typically use two-stage modulation either via a quad jet approach (where there are two pairs of jets to trap and release the analytes on two different sections of the column) or a delay loop (where the column loops back between a single pair of jets). Both approaches ensure there are two opportunities to focus the analytes. There are also different versions of thermal modulators based on what is used to cool the cold jet (a stream of dry gas, usually air or nitrogen). Liquid nitrogen cooled loop system provide the lowest temperature for thermal modulation, meaning it is capable of modulating volatiles from C2. However, there is the compromise that liquid nitrogen is expensive and causes additional health and safety concerns. Alternatively, consumable-free thermal modulators are available that use a closed cycle refrigeration unit to cool the cold jet.
=== Project REWARD === The REWARD (Real time wide area radiation surveillance system) project was established to address the threats of nuclear terrorism, missing radioactive sources, radioactive contamination and nuclear accidents. The consortium developed a mobile system for real time wide area radiation monitoring based on the integration of new miniaturized solid state sensors. Two sensors are used: a cadmium zinc telluride (CdZnTe) detector for gamma radiation and a high efficiency neutron detector based on novel silicon technologies. The gamma and neutron detectors are integrated into a single monitoring device called a tag. The sensor unit includes a wireless communication interface to remotely transmit data to a monitoring base station, which also uses a GPS system to calculate the tag's position.
Label-free quantification is a method in mass spectrometry that aims to determine the relative amount of proteins in two or more biological samples. Unlike other methods for protein quantification, label-free quantification does not use a stable isotope containing compound to chemically bind to and thus label the protein.
Sources: en.wikipedia.org
Adrian McKinty (born 1968) is a Northern Irish writer of crime and mystery novels and young adult fiction, best known for his 2019 award-winning thriller, The Chain, and the Sean Duffy novels set in Northern Ireland during The Troubles. He is a winner of the Edgar Award, the Theakston Old Peculier Crime Novel of the Year Award, the Macavity Award, the Ned Kelly Award, the Barry Award, the Audie Award, the Anthony Award and the International Thriller Writers Award. He has been shortlisted for the CWA Ian Fleming Steel Dagger and the Grand Prix de Littérature Policière.
Brazil also fields the R3 Emergency Operation Ration (Portuguese: Ração Operacional de Emergência – R3), a 12-hour ration to be used in situations where cooked foods cannot be provided for all meals. The R3 ration is similar to the R2 and uses the same components, but contains less food. The bag is printed with the emblem of the Brazilian Army, "Emergency Ration R3 (12 hours)" (Portuguese: Ração de Emergência R3 (12 Horas)) and Menu information. Inside are 3 thin plastic bags: 2 meal bags and 1 accessory packet.
Natural freshwater diatomaceous earth is preferred by many researchers over chromic oxide, which has been widely used for the same purpose, the latter being a known carcinogen and, therefore, a potential hazard to research personnel.
In 1926, the Portway, a new road along the Avon Gorge built at a cost of around £800,000, was opened linking the floating harbour to the expanding docks at Avonmouth. As the location of aircraft manufacture and a major port, Bristol was a target of bombing during the Bristol Blitz of World War II. Bristol's city centre also suffered severe damage, especially in November and December 1940, when the Broadmead area was flattened, and Hitler claimed to have destroyed the city. The original central area, near the bridge and castle, is still a park featuring two bombed out churches and some fragments of the castle. Slightly to the north, the Broadmead shopping centre and Cabot Circus were built over bomb-damaged areas. About 1,300 people living or working in the city were killed, and nearly 100,000 buildings were damaged, at least 3,000 beyond repair. As with other British cities, there was immigration from various Commonwealth countries in the post war years, which did lead to some racist tension. In 1963, a colour bar operated by Bristol Omnibus Company, which at that time refused to employ Black or Asian bus crews, was successfully challenged in the Bristol Bus Boycott, which was considered to have been instrumental in the eventual passage of the Race Relations Act 1968. In 1980 a police raid on a cafe in St Paul's sparked the St Pauls riot, which highlighted the alienation of the city's ethnic minorities. Bristol aviation continued to develop in post war years.
Sources: en.wikipedia.org
== Personal life == Platt married Mary Camilla Bonsal Campbell on September 12, 1992, at the First Congregational Church in Kittery, Maine. They have three children. As of 1998, Platt had an open airline ticket when filming so he could return home frequently because his family did not accompany him to filming locations. In a 1999 interview, Platt explained that he had chosen to focus on film and television rather than theater because of his family. Platt has a home in North Haven, Maine.
=== Solid === Solid stainless-steel belts are, as standard, delivered in cold-rolled condition with a mill finish of Ra < 0.4 μm and have rounded edges. Carbon steel belts are, as standard, delivered in a hardened and tempered condition with a mill finish of Ra < 0.4 μm and have rounded edges. Solid steel belts are leveled and straightened to obtain flatness and straightness and are supplied in open lengths, with the ends prepared for welding on site, or in endless condition with a welded joint.
Lorcaserin is a selective 5-HT2C receptor agonist, and in vitro testing of the drug showed reasonable selectivity for 5-HT2C over other related targets. 5-HT2C receptors are located almost exclusively in the brain, and can be found in the choroid plexus, cortex, hippocampus, cerebellum, amygdala, thalamus, and hypothalamus. The activation of 5-HT2C receptors in the hypothalamus is supposed to activate proopiomelanocortin (POMC) production and consequently promote weight loss through satiety. This hypothesis is supported by clinical trials and other studies. While it is generally thought that 5-HT2C receptors help to regulate appetite as well as mood, and endocrine secretion, the exact mechanism of appetite regulation was not known as of 2005. Lorcaserin has shown 100x selectivity for 5-HT2C versus the closely related 5-HT2B receptor, and 17x selectivity over the 5-HT2A receptor.
=== Portal: The Uncooperative Cake Acquisition Game === A board game version of Portal, developed by Cryptozoic Entertainment with oversight from Valve, was released in 2015. Titled Portal: The Uncooperative Cake Acquisition Game, the game tasks players with manipulating their tokens—representing unwitting test subjects—through various test chambers in Aperture Laboratories. The primary goal is to acquire cake slices by successfully navigating subjects through the chambers. The basic gameplay loop involves moving subjects toward the opposite end of the board's tiles. These tiles are slowly recycled and moved back to the start, making the board function like a conveyor belt. When a tile is recycled at the end of the track, the player with the most subjects on that tile receives its associated rewards. Players must then protect their acquired cake slices from opponents, who can attempt to dispose of them by recycling the test chambers they reside in or by incinerating them using action cards. Additionally, the game features portals for faster movement, a Weighted Companion Cube that distracts subjects and prevents reward acquisition on its occupied tile, and a turret that eliminates all subjects on its tile. The game ends when a player runs out of either test subjects or cake slices, at which point the player with the most accumulated cake slices is declared the winner. In the event of a tie, the tied player with the most remaining test subjects wins.
Antidepressant discontinuation syndrome, or antidepressant withdrawal, is a condition that can occur following switching, reducing, or discontinuing an antidepressant medication following its continuous use of at least a month. The symptoms may include dizziness, vertigo, postural orthostatic tachycardia syndrome (POTS), tinnitus, insomnia, nausea, poor balance, sensory changes, "brain zaps", emotional lability or extreme emotional changes, rage, suicidal ideation, akathisia, dysesthesia, intrusive thoughts, depersonalization and derealization, mania, anxiety, depression, stuttering, and flu-like symptoms. Psychosis may rarely occur. Depending on the specific antidepressant's half-life, withdrawal can begin within a few days or weeks, but late onset or delayed onset withdrawal can occur months after cessation. If stopped too quickly, a withdrawal injury can occur. This is referred to as protracted withdrawal and may last for several months or years. Discontinuation syndrome was coined by Eli Lilly as a way to distance antidepressants from other dependence-forming psychotropics with higher addiction risk profiles. However, the evidence supports that what has been mislabeled as discontinuation syndrome is a classical withdrawal syndrome similar to that of benzodiazepines. Antidepressants are not addictive and do not produce substance use disorders, but they do create physical dependence which occurs when the body makes neuroadaptations due to the presence of the drug.
Sources: en.wikipedia.org
Liquid chromatography–mass spectrometry is commonly used. It provides molecular mass and purity information. Other methods may include HPLC with ultraviolet detection.
Dihexa is often described as an HGF mimetic that activates c-Met signaling. Some research also links it to angiotensin IV pathways. The precise targets and human relevance remain uncertain.
The powder is typically stored at -20 °C, desiccated and protected from light. Avoid repeated freeze-thaw cycles. Follow supplier instructions and institutional guidelines.
Dihexa is a synthetic peptide analog related to angiotensin IV. It is studied in preclinical research for effects on neural signaling and synapse formation. It is not an approved medicine.